Mosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: Beta-2 adrenergic agonists

References

• Bensimon G, Lacomblez L, Meininger V, and the ALS/Rilu- zole study group. A controlled trial of riluzole in amy- otrophic lateral sclerosis. N Engl J Med 1994; 330: 585–591.
   Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, and the ALS/Riluzole study group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 345: 1425–1431.
   Google Scholar
• Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-1 on progression of ALS: a placebo-controlled study. Neurology 1997; 49: 1621–1630.
   PubMed Web of Science ®Google Scholar
• Miller R, Gelinas D, Moore D, et al. A phase III Placebo-contolled Trial of gabapentin in amyotrophic lateral sclerosis. Ann Neurol 1999; 46: 494.
   Google Scholar
• Miller RG, Moore D, Young LA, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral scler- osis. Neurology 1996; 47: 1383–1388.
   PubMed Web of Science ®Google Scholar
• Strong MJ, Pattee GL. Creatine and coenzyme Q10 in the treatment of amyotrophic lateral sclerosis. ALS 2000; 1 (suppl 4): 17–20.
   Google Scholar
• Buchweitz-Milton E, Weiss HR. Effect of salbutamol on regional cerebral oxygen consumption, flow and capillary and arteriolar perfusion. Neurol Res 1990; 12: 169–175.
   PubMedGoogle Scholar
• Pons L, Trenque T, Bielecki M, Moulin M, Potier JC. Atten- tional effects of caffeine in man: comparison with drugs acting upon performance. Psych Res 1988; 23: 329–333.
   Google Scholar
• Doheny MH, Waterfield CJ, Timbrell JA. The effects of the beta 2-agonist drug clenbuterol on taurine levels in heart and other tissues in the rat. Amino Acids. 1998; 15: 13–25.
   Google Scholar
• Yoshino Y, Koike H, Akai K. Free amino acids in motor cortex of amyotrophic lateral sclerosis. Experimentia 1979; 15: 219–220.
   Google Scholar
• Yoshino Y. Possible involvement of folate cycle in the patho- genesis of amyotrophic lateral sclerosis. Neurochem Res 1984; 9: 387–91.
   PubMed Web of Science ®Google Scholar
• Perry TL, Bergeron C, Steele JC, McLachlan DR, Hansen S. Brain amino acid contents are dissimilar in sporadic and Guamanian amyotrophic lateral sclerosis. J Neurol Sci 1990; 99: 3–8.
   Google Scholar
• Malessa S, Leigh PN, Bertal O, Sluga E, Homykiewicz O. Amyotrophic lateral sclerosis: glutamate dehydrogenase and transmitter amino acids in the spinal cord. J Neurol Neuro- surg Psychiatr 1991; 54: 984–988.
   Google Scholar
• Fujita K, Nagata Y, Honda M. Free amino acid contents in the spinal cord of amyotrophic lateral sclerosis. Rinsho Shinkeigaku 1993; 33: 1985–1987.
   Google Scholar
• Kuroda K. Effects of excitatory sulfur amino acids on gluta- mate transport in synaptosomes isolated from the rat cereb- ral cortex. Rinsho Shinkeigaku 1998; 38: 1019–1023.
   Google Scholar
• Martin DL, Shain W. Beta-adrenergic-agonist stimulated taurine release from astroglial cells is modulated by extracellu- lar [K+] and osmolarity. Neurochem Res 1993; 18: 437–434.
   Google Scholar
• Waterfield CL, Jairath M, Asker DS, Timbrell JA. The biochem- ical effects of clenbuterol: with particular reference to taurine and muscle damage. Eur J Pharmacol 1995; 293: 141–149.
   PubMedGoogle Scholar
• Bastos ML, Carvalho F, Remiao F et al. Changes in taurine levels in response to repeated administration of the beta 2–agonist salbutamol in lambs. J Vet Pharm Ther 1997; 20: 33–37.
   Google Scholar
• Saransaari P, Oja SS. Taurine release is enhanced in cell- damaging conditions in cultured cerebral cortical astrocytes. Neurochem Res 1999; 24: 1523–1529.
   Google Scholar
• Do KO, Benz B, Sorg O, Pellerin L, Magistretti PJ. beta- Adrenergic stimulation promotes homocysteic acid release from astrocyte cultures: evidence for a role of astrocytes in the modulation of synaptic transmission. J Neurochem 1997; 68: 2386–2394.
   Google Scholar
• Feinstein DL, Rozelman E. Norepinephrine suppresses L- arginine uptake in rat glial cells. Neurosci Lett. 1997; 223: 37–40.
   Google Scholar
• Nakamura A, Johns EJ, Imaizumi A, Abe T, Koshaka T. Regu- lation of tumour necrosis factor and interleukin–6 gene tran- scription by beta 2–adrenoceptor in the rat astrocytes. J Neuroimmunol 1998; 88: 144–153.
   PubMed Web of Science ®Google Scholar
• Raofi S, Wong PK, Wilcox RE. Modulation of G-protein linked cAMP accumulation in immortalized murine cortical astrocytes by retroviral infection. Brain Res 2000; 862: 230–233.
   PubMed Web of Science ®Google Scholar
• Furukawa Y, Tomioka N, Sato W, Satoyoshi E, Hayashi K, Furukawa S. Catecholamines increase nerve growth factor mRNA content in both mouse astroglial cells and fibroblast cells. FEBS Lett. 1989; 247: 463–467.
   PubMed Web of Science ®Google Scholar
• Delumeau JC, Marin P, Cordier J, Glowinski J, Premont J. Synergistic effects in the alpha 1- and beta 1-adrenergic regu- lation of intracellular calcium levels in striatal astrocytes. Cell Mol Neurobiol 1991; 11: 263–276.
   Google Scholar
• Ricks CA, Dalrymple RH, Baker DK, Ingle DL. Use of Beta-2 agonist to alter fat and muscle deposition in steers. J Animal Sci 1984; 59: 1247–1255.
   Web of Science ®Google Scholar
• Jones RW, Easter RA, McKeith FK, Dalrymple RH, Maddock HM, Bechtel PJ. Effect of the beta-adrenergic agonist cimaterol (CL 263, 780) on the growth and carcass characteristics of finishing swine. J Anim Sci 1985; 61: 905–913.
   PubMed Web of Science ®Google Scholar
• Reeds PJ, Hay SM, Dorward PM, Palmer RM. Stimulation of muscle growth by clenbuterol: lack of effect on muscle protein biosynthesis. Br J Nutr 1986; 56: 249–258.
   PubMed Web of Science ®Google Scholar
• Kim YS, Lee TH, Choi YJ. Effect of intermittent and stepwise administration of a beta-adrenergic agonist, L644, 969, on rat growth performance and skeletal muscles. Comp Biochem Physiol 1995; 110C: 127–132.
   Google Scholar
• Yang YT, McElligott MA. Multiple actions of beta-adrenergic agonist on skeletal muscle and adipose tissue. Biochem J 1989; 261: 1–10.
   PubMed Web of Science ®Google Scholar
• Eadara JK, Dalrymple RH, Delay RL, Ricks CA, Rasmosos DR. Effects of cimaterol, a beta-adrenergic agosnist on protein metabolism in rats. Metab Clin Exp 1989; 28: 883–890.
   Google Scholar
• Maltin CA, Delday MI, Reeds PJ. The effect of a growth pro- moting drug, clenbuterol, on fiber frequency and area in hind limb muscles from young male rats. Biosci Reports 1986; 6: 293–299.
   PubMed Web of Science ®Google Scholar
• Zeman RJ, Ludeman R, Easton TG, Etlinger JD. Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta 2-receptor agonist. Am J Physiol 1988(254): EE726–732.
   Google Scholar
• Emery PW, Rothwell NJ, Stock MJ, Winter PD. Chronic effects of beta-2-adrenergic agonists on body composition and protein synthesis in the rat. Biosci Reports 1984; 4: 83–91.
   PubMed Web of Science ®Google Scholar
• Reeds PJ, Hay SM, Dorward PM, Palmer RM. The effect of beta-agonists and antagonists on muscle growth and body composition of young rats (Rattus sp.). Comp Biochem Physiol 1988; 89C: 337–341.
   Google Scholar
• Zeman RJ, Ludemann R, Etlinger JD. Clenbuterol, a beta 2- agonist, retards atrophy in denervated muscles. Am J Physiol 1987; 252: E152–E155.
   PubMedGoogle Scholar
• Maltin CA, Reeds PJ, Delday MI, Hay SM, Smith FG, Lobley GE. Inhibition and reversal of denervation induced atrophy by the beta-2 agonist growth promoter, clenbuterol. Biosci Reports 1986; 6: 811–818.
   PubMed Web of Science ®Google Scholar
• Agbenyega ET, Wareham AC. Effect of clenbuterol on skele- tal muscle atrophy in mice induced by the glycocorticoid dexamethasone. Comp Biochem Physiol 1992; 102: 141–145.
   Google Scholar
• Rothwell NJ, Stock MJ. Effect of a selective beta-2-adrenergic agonist (clenbuterol) on energy balance and body composi- tion in normal and protein deficient rats. Biosci Reports 1987; 7: 933–940.
   PubMed Web of Science ®Google Scholar
• Choo JJ, Horan MA, Little RA, Rothwell NJ. Effects of the beta-2-adrenoreceptor agonist, clenbuterol, on muscle atrophy due to food deprivation in the rat. Metab Clin Exp 1990; 39: 647–650.
   PubMed Web of Science ®Google Scholar
• Costelli P, Garcia-Martinez C, Llovera M, et al. Muscle protein waste in tumor-bearing rats is effectively antago- nized by a beta -2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest 1995; 95: 2367–2372.
   Google Scholar
• Choo JJ, Horan MA, Little RA, Rothwell NJ. Muscle wasting associated with endotoxemia in the rat: modification by the beta-2-adrenoreceptor agonist clenbuterol. Biosci Reports 1989; 9: 615–621.
   PubMed Web of Science ®Google Scholar
• Carter WJ, Dang AQ, Faas FH, Lynch ME. Effects of clen- buterol on skeletal muscle mass, body composition, and recovery from surgical stress in senescent rats. Metab Clin Exp 1991; 40: 855–860.
   PubMed Web of Science ®Google Scholar
• Rothwell NJ, Stock MJ. Modification of body composition by clenbuterol in normal and dystrophic (mdx) mice. Biosci Reports 1985; 5(9): 755–760.
   Google Scholar
• Dupont-Versteegden EE. Exercise and clenbuterol as strat- egies to decrease the progression of muscular dystrophy in mdx mice. J Applied Physiol 1996; 80: 734–741.
   PubMed Web of Science ®Google Scholar
• Maltin CA, Hay SM, Delday MI, Lobley GE, Reeds PJ. The action of the beta–agonist clenbuterol on protein metabo- lism in innervated and denervated phasic muscles. Biochem J 1989; 261: 965–971.
   PubMedGoogle Scholar
• Hesketh JE, Campbell GP, Lobley GE, et al. Stimulation of actin and myosin synthesis in rat gastrocnemius muscle by clenbuterol; evidence for translational control. Comp Biochem Physiol 1992; 102: 23–27.
   Google Scholar
• Maltin CA, Delday MI. Satellite cells in innervated and den- ervated muscles treated with clenbuterol. Muscle Nerve 1992; 15: 919–925.
   PubMedGoogle Scholar
• McLennan PA, Edwards RH. Clenbuterol induces a propra- nolol-sensitive accumulation of actin message in rat skeletal muscle. Biochem Soc Trans 1992; 20: 191.
   Google Scholar
• Benson DW, Foley-Nelson T, Charnace WT, et al. Decreased myofibrillar protein breakdown following treatment with clenbuterol. J Surg Res 1991; 50: 1–5.
   PubMed Web of Science ®Google Scholar
• Roberts P, McGeachie JK. The effects of clenbuterol on setal- lite cell activation and the regenertion of skeletal muscle: an autoradiographic and morphometric study of whole muscle transplants in mice. J Anat 1992; 180: 57–65.
   PubMed Web of Science ®Google Scholar
• Maltin CA, Hay SM, McMillan DN, Delday MI. Tissue spe- cific responses to clenbuterol; temporal changes in protein metabolism of striated muscle and visceral tissues from rats. Growth Regul 1992; 2: 161–166.
   PubMedGoogle Scholar
• McElligott MA, Barreto A Jr, Chaung L-Y. Effect of continu- ous and intermittent clenbuterol feeding on rat growth rate and muscle.Comp Biochem Physiol 1989; 92: 135–138.
   Google Scholar
• Fellenius E, Hedberg R, Holmberg E, Waldeck B. Functional and metabolic effects of terbatuline and propranolol in fast- and slow-contracting skelatal muscle in vitro. Act Physiol Scand 1980; 109: 89–95.
   Google Scholar
• Holmerg E, Waldeck B. Analysis of the beta-receptor medi- ated effects on fast-contracting skelatal muscle in vitro. Naunyn Schmeideberg’s Arch Pharm 1977; 301: 109–113.
   Google Scholar
• Choo JJ, Horan MA, Little RA, Rothwell NJ. Anabolic effects of clenbuterol on skeletal muscle mediated by beta-2- adrenoreceptor activation. Am J Physiol 1992; 263: E50–E60.
   PubMed Web of Science ®Google Scholar
• Prakash YS, van der Heijden HF, Gallant EM, Sieck GC. Effect of beta-adrenoceptor activation on [Ca2+]i regulation in murine skeletal myotubes. Am J Physiol 1999; 276: C1038–C1045.
   Google Scholar
• Van der Heijden HF, Heunks LM, Folgering HT, Van Her- waarden CL, Dekhuijzen PN. Beta-2-adrenoreceptor agonists reduce the decline of rat diaphragm twitch force during severe hypoxia. Am J Physiol 1999; 276 (3Pt1): L474–L480.
   Google Scholar
• Wright LD, Zhang KM, McClain LC, Hsia PW, Briggs FN, Spratt JA. Salbutamol and the conditioning of latissimus dorsi for cardiomyoplasty. J Surg Res 1999; 81: 209–215.
   Google Scholar
• Murphy RJ, Hartkopp A, Gardiner PF, Kjaer M, Beliveau L. Salbutamol effect in spinal cord injured individuals under- going functional electrical stimulation training. Arch Phys Med Rehabil 1999; 80: 1264–1267.
   PubMed Web of Science ®Google Scholar
• Martinneau L, Horan MA, Rothwell NJ, Little RA. Salbuta- mol, a beta–2 adrenoreceptor agonist, increases skeletal muscle strength in young men. Clini Sci 1993; 83: 615–654.
   Google Scholar
• Caruso JF, Signorile JF, Perry AC, et al. The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Med Sci Sports Exercise 1995; 27: 1471–1476.
   PubMed Web of Science ®Google Scholar
• Kissel JT, McDermott MP, Natarajan MA, et al. Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. Neu- rology 1998; 50: 1402–1406.
   Google Scholar
• Kissel JT, McDermott MP, Natarajan R et al. Placebo-con- trolled clinical trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group. American Academy of Neurology Scientific Program Works in Progress Abstract Session, San Diego, 2000.
   Google Scholar
• Wang P, Clausen T, Orskov H. Salbutamol inhalations sup- press attacks of hyperkalemia in familial periodic paralysis. Monogr Hum Genet 1978; 10: 62–65.
   PubMedGoogle Scholar
• Vincent HM, Boomsma F, Man in’t Veld AJ, Derkx FH, Wenting GJ, Schalekamp MA. Effects of selective and nonse- lective beta-agonists on plasma potassium and norepineph- rine. J Cardiovasc Pharmacol 1984; 6: 107–114.
   Google Scholar
• Schaffler K, Reeh PW. Induction and reduction of muscle tremor upon acute and repeated administration of the beta 2-agonists terbutaline, salbutamol and tulobuterol. Int J Clin Pharmacol Ther Toxicol 1987; 25: 673–682.
   PubMedGoogle Scholar
• Lisi DM. Muscle spasms and creatine phosphokinase eleva- tion following salbutamol administration. Eur Respir J 1989; 2: 98.
   PubMedGoogle Scholar
• Al-Damluji S, Perry L, Tomlin S, Bouloux P, Grossman A, Rees LH, Besser GM. Alpha-adrenergic stimulation of corti- cotropin secretion by a specific central mechanism in man. Neuroendocrinol 1987; 45: 68–76.
   Google Scholar
• Brooks BR, Sanjak M, Belden D, et al. Natural history of amyotrophic lateral sclerosis–impairment, disability, handi- cap. In: Brown RH, Meininger V, Swash M, Eds. Amyotrophic Lateral Sclerosis. London: Martin Dunitz, 2000.
   Google Scholar
• Bloomfield SA, Girten BE, Weisbrode SE. Effects of vigorous exercise training and beta-agonist administration on bone response to hindlimb suspension. J Appl Physiol 1997; 83: 172–178.
   Google Scholar
• Sullivan MJ, Binkley PF, Unverferth DV et al. Prevention of bedrest-induced physical deconditioning by daily dobuta- mine infusions. Implications for drug-induced physical con- ditioning. J Clin Invest 1985; 76: 1632–1642.
   Google Scholar